Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 30, 2016

Primary Completion Date

June 20, 2022

Study Completion Date

June 20, 2022

Conditions

Clear Cell Renal Cell CarcinomaMetastatic Renal Cell CancerStage IV Renal Cell Cancer AJCC v7

Interventions

PROCEDURE

Cryosurgery

Undergo cryoablation

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

BIOLOGICAL

Tremelimumab

Given IV

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02626130 - Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter